Somapacitan (Sogroya®). HTA ID: 23060

Assessment Status Rapid Review Complete
HTA ID 23060
Drug Somapacitan
Brand Sogroya®
Indication Somapacitan (Sogroya®) is indicated for the replacement of endogenous growth hormone in children aged three years and above and adolescents with growth failure due to growth hormone deficiency (GHD), and in adults with GHD.
Assessment Process
Rapid review commissioned 25/09/2023
Rapid review completed 27/11/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that somapacitan not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.